Molecular classification of pulmonary sarcomatoid carcinomas suggests new therapeutic opportunities

Pulmonary sarcomatoid carcinoma (SC) is a rare disease with poor prognosis and with strong inter- and intratumor heterogeneity. However, molecular classification is currently focused on activating MET mutations. We sought to better characterize the molecular diversity of SC using mutational signatur...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 2017-07, Vol.28 (7), p.1597-1604
Hauptverfasser:	Pécuchet, N., Vieira, T., Rabbe, N., Antoine, M., Blons, H., Cadranel, J., Laurent-Puig, P., Wislez, M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - therapeutic use Biomarkers, Tumor - genetics Carcinosarcoma - classification Carcinosarcoma - drug therapy Carcinosarcoma - genetics Carcinosarcoma - pathology classification Cluster Analysis DNA Mutational Analysis Female Gene Expression Profiling - methods Genetic Predisposition to Disease Humans lung cancer Lung Neoplasms - classification Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - pathology Male Molecular Targeted Therapy mutagenesis Mutation mutational signature Phenotype Precision Medicine Predictive Value of Tests Risk Factors sarcomatoid Signal Transduction - drug effects Signal Transduction - genetics Whole Exome Sequencing
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!